Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIAT
Ratios

GT Biopharma (GTBP) EBIAT (2016 - 2021)

GT Biopharma (GTBP) has disclosed EBIAT for 12 consecutive years, with -$27.3 million as the latest value for Q4 2021.

  • On a quarterly basis, EBIAT fell 847.98% to -$27.3 million in Q4 2021 year-over-year; TTM through Dec 2021 was -$58.0 million, a 298.85% decrease, with the full-year FY2025 number at -$28.4 million, down 115.77% from a year prior.
  • EBIAT was -$27.3 million for Q4 2021 at GT Biopharma, down from -$5.5 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $4.4 million in Q2 2021 to a low of -$235.8 million in Q3 2018.
  • A 5-year average of -$26.9 million and a median of -$5.5 million in 2021 define the central range for EBIAT.
  • Biggest YoY gain for EBIAT was 181.19% in 2021; the steepest drop was 1637.53% in 2021.
  • GT Biopharma's EBIAT stood at -$6.0 million in 2017, then crashed by 3812.76% to -$235.8 million in 2018, then surged by 99.38% to -$1.5 million in 2019, then plummeted by 95.65% to -$2.9 million in 2020, then tumbled by 847.98% to -$27.3 million in 2021.
  • Per Business Quant, the three most recent readings for GTBP's EBIAT are -$27.3 million (Q4 2021), -$5.5 million (Q3 2021), and $4.4 million (Q2 2021).